🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

27 results for “Adaptive” Clear

  1. ADI-PEG-20, Troriluzole, AZD1390

    Adaptive Biotechnologies Corp

    Oncology - Glioblastoma (GBM)

    phase 3 small molecule active

    1 trial

  2. Ceftriaxone

    Adaptive Biotechnologies Corp

    Community-acquired Pneumonia, Influenza, COVID-19

    phase 3 small molecule active

    1 trial

  3. Temozolomide

    Adaptive Biotechnologies Corp

    Glioblastoma

    phase 3 small molecule active

    1 trial

  4. A Dose-Finding, Adaptive, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Idiopathic Hypersomnia (IH)

    Takeda Pharmaceuticals International AG

    Idiopathic Hypersomnia (IH)

    phase 2 other active

    1 trial

  5. A Randomized, Double-Blinded, Placebo-Controlled, Dose-Finding, Adaptive Trial to Evaluate the Safety, Tolerability, and Efficacy of TAK-360 in Participants with Narcolepsy without Cataplexy (NT2)

    Takeda Pharmaceuticals International AG

    Narcolepsy without Cataplexy (NT2)

    phase 2 other active

    1 trial

  6. Acoustic CR-Stimulator ANM//Technology: Acoustic coordinated reset

    Adaptive Biotechnologies Corp

    Chronic Tonal Tinnitus

    phase 2 other completed

    1 trial

  7. Adaptive-Planning Organ Localisation (A-POLO) (Planning CT scan)

    United Therapeutics Europe Ltd

    Bladder Cancer

    phase 2 other active

    1 trial

  8. An Adaptive Dose Escalation and Expansion Basket Trial to Explore the Safety, Pharmacology, and Clinical Activity of TGD001 in Immune-Mediated Thrombotic Thrombocytopenic Purpura (iTTP) and Other Thrombotic Microangiopathies

    Pharma Mar S.A.

    Immune-Mediated Thrombotic Thrombocytopenic Purpura, Thrombotic microangiopathy

    phase 2 other active

    1 trial

  9. Bacteriophage

    Adaptive Biotechnologies Corp

    Prosthetic Joint Infection

    phase 2 small molecule terminated

    1 trial

  10. Bacteriophage Therapy

    Adaptive Biotechnologies Corp

    Urinary Tract Infection Bacterial

    phase 2 mab terminated

    1 trial

  11. Bacteriophage Therapy

    Adaptive Biotechnologies Corp

    Osteomyelitis

    phase 2 mab terminated

    1 trial

  12. Bendamustine

    Adaptive Biotechnologies Corp

    Lymphoma

    phase 2 small molecule active

    1 trial

  13. Intervention A Fluoxetine Hydrochloride (HCl)

    Adaptive Biotechnologies Corp

    Post Traumatic Stress Disorder

    phase 2 small molecule active

    2 trials

  14. Intervention B Vilazodone Hydrochloride (HCl)

    Adaptive Biotechnologies Corp

    Post Traumatic Stress Disorder

    phase 2 small molecule active

    1 trial

  15. Intervention C Daridorexant

    Adaptive Biotechnologies Corp

    Post Traumatic Stress Disorder

    phase 2 small molecule active

    1 trial

  16. Intervention D SLS-002

    Adaptive Biotechnologies Corp

    Post Traumatic Stress Disorder

    phase 2 small molecule on hold

    1 trial

  17. Mosunetuzumab

    Adaptive Biotechnologies Corp

    Diffuse Large B-Cell Lymphoma (DLBCL)

    phase 2 small molecule active

    1 trial

  18. Nivolumab

    Adaptive Biotechnologies Corp

    Bladder Cancer

    phase 2 small molecule completed

    1 trial

  19. Obinutuzumab

    Adaptive Biotechnologies Corp

    Mantle Cell Lymphoma

    phase 2 mab active

    1 trial

  20. Phage Therapy

    Adaptive Biotechnologies Corp

    Prosthetic Joint Infection

    phase 2 mab terminated

    2 trials

  21. Varenicline Adaptive Protocol

    BRIGHT MINDS BIOSCIENCES INC.

    Nicotine Dependence

    phase 2 small molecule completed

    1 trial

  22. Venetoclax monotherapy

    Adaptive Biotechnologies Corp

    Chronic Lymphocytic Leukemia (CLL)

    phase 2 small molecule active

    1 trial

  23. online adaptive radiotherapy

    First Tracks Biotherapeutics

    Cervical Cancer

    phase 2 other active

    1 trial

  24. AN OPEN-LABEL, RANDOMIZED, SINGLE DOSE, TWO-STAGE CROSSOVER ADAPTIVE BIOEQUIVALENCE STUDY OF TRIAMCINOLONE ACETONIDE 40 MG/ML STERILE INJECTABLE SUSPENSION (Test product–Lisapharma S.p.A) VERSUS KENACORT® 40 MG/ML SUSPENSION (Reference product – Bristol Myers Squibb) AFTER INTRAMUSCULAR ADMINISTRATION TO HEALTHY VOLUNTEERS

    Pharma Mar S.A.

    Intramuscular administration of triamcinolone acetonide Lisapharma (Injectable suspension of triamcinolone acetonide) is indicated for systemic corticosteroid therapy in morbid conditions such as allergic syndrome (to control severe or debilitating conditions not treatable in a conventional way), dermatoses, generalized rheumatoid arthritis and other connective tissue diseases.

    phase 1 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources